IDEX Corporation (NYSE: IEX) shares climbed modestly in early trading. This happened right after the company released its fourth-quarter and full-year 2025 earnings. In fact, the stock climbed about 2% during intraday trading. Moreover, it outperformed recent flat trends. However, it still lagged broader industrial peers over the past 52 weeks. Over the last year, for example, IEX shares underperformed many benchmarks. Investors showed caution because of weak industrial demand.
Q4 and Full-Year Results
IDEX reported record Q4 sales of $899.1 million. These sales increased 4% from the year-ago period. Organically, they grew 1%. Adjusted diluted EPS hit $2.10, up 3%. This beat the Street consensus estimate of $2.04. Reported diluted EPS reached $1.71, rising 6% year-over-year. Orders surged to $979 million. They climbed 20% on a reported basis and 16% organically. chiefly, strength in the Health & Science Technologies (HST) segment drove this.
For full-year 2025, IDEX achieved record sales of about $3.46 billion. Sales rose 6% overall, and organic sales grew about 1%. Adjusted diluted EPS increased 1% to $7.95. However, reported diluted EPS fell 3% to $6.41. Operating cash flow grew 2% to $680 million. Free cash flow also rose 2% to roughly $617 million. Conversion exceeded 100% of net income. Additionally, share repurchases totaled $248 million for the year.
Segment and Margin Highlights
Organic revenue gains focused on the HST segment in the quarter. This segment saw robust order growth. Demand in data centers, semiconductors, and other tech markets fueled it. Fluid & Metering Technologies (FMT) posted modest gains. Meanwhile, the Fire & Safety/Diversified Products segment saw a slight organic sales decline. Adjusted EBITDA margins expanded modestly. Pricing actions, cost productivity, and operational improvements helped achieve this.
Outlook and Guidance
Management projected 2026 organic sales growth of 1%–2%. They also forecasted adjusted diluted EPS between $8.15 and $8.35. For the first quarter, organic growth nears 1%, with EPS of $1.73–$1.78. Overall, this outlook signals moderate growth. Yet, it faces ongoing industrial headwinds.
Analyst Activity
Analysts made no material upgrades, downgrades, or price-target changes after today’s results. This occurred as of market open. Consensus estimates had expected the earnings and revenue beat.
Stock Performance Context
Over the past year, IEX shares lagged broader indices. Uneven demand in industrial end markets caused this. Even so, specialized segments like health and science technologies showed momentum.